European Medicines Agency approves olaparib for women with BRCA-mutant breast cancer – 15 months after licensing in the US.

Women with an aggressive form of breast cancer who have faults in their BRCA genes do much better on chemotherapy drug carboplatin than standard treatment, a major clinical trial reports.

The identified gene was one of 37 new genes that the researchers found triple-negative breast cancers were 'addicted to'.